富吉瑞(688272.SH):擬通過增資和受讓獲取北方廣微10%股權
格隆匯1月10日丨富吉瑞(688272.SH)公佈,公司與北方廣微科技有限公司(“北方廣微”)及其股東廣微控股有限公司(“廣微控股”)簽署《投資意向協議》,公司以現金方式向北方廣微增資同時受讓廣微控股持有的北方廣微部分股權,上述交易完成後公司持有北方廣微10%股權。
根據意向協議約定,公司先行向公司與廣微控股的共管賬户支付合作意向金500萬元人民幣,待簽署正式協議,且公司已按正式協議相關約定支付首期款項時全額退還公司。
北方廣微系國內主要非製冷紅外探測器研發和製造企業之一,也是公司長期合作的主要供應商。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.